Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.

Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL.

Breast Cancer Res. 2018 Jun 14;20(1):52. doi: 10.1186/s13058-018-0989-8.

2.

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.

Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

J Clin Invest. 2018 Jun 1;128(6):2376-2388. doi: 10.1172/JCI97924. Epub 2018 Apr 30.

3.

Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy.

Patel BK, Hilal T, Covington M, Zhang N, Kosiorek HE, Lobbes M, Northfelt DW, Pockaj BA.

Ann Surg Oncol. 2018 May;25(5):1350-1356. doi: 10.1245/s10434-018-6413-x. Epub 2018 Mar 7.

PMID:
29516362
4.

Choosing wisely after publication of level I evidence in breast cancer radiotherapy.

Niska JR, Keole SR, Pockaj BA, Halyard MY, Patel SH, Northfelt DW, Gray RJ, Wasif N, Vargas CE, Wong WW.

Breast Cancer (Dove Med Press). 2018 Feb 9;10:31-37. doi: 10.2147/BCTT.S153117. eCollection 2018.

5.

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA.

Ann Oncol. 2018 Jan 29. doi: 10.1093/annonc/mdx811. [Epub ahead of print] No abstract available.

PMID:
29390054
6.

A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.

Sonbol MB, Hilal T, Dueck AC, Rosenthal AC, Conley CR, Kosiorek HE, Ginos BF, Gano KM, Nichols CS, Leis JF, Johnston PB, Habermann TM, Northfelt DW, Bergsagel PL, Inwards DJ, Witzig TE, Ansell SM, Reeder CB.

Leuk Lymphoma. 2018 Jan 10:1-7. doi: 10.1080/10428194.2017.1416368. [Epub ahead of print]

PMID:
29320913
7.

Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.

Yu J, Qin B, Moyer AM, Sinnwell JP, Thompson KJ, Copland JA 3rd, Marlow LA, Miller JL, Yin P, Gao B, Minter-Dykhouse K, Tang X, McLaughlin SA, Moreno-Aspitia A, Schweitzer A, Lu Y, Hubbard J, Northfelt DW, Gray RJ, Hunt K, Conners AL, Suman VJ, Kalari KR, Ingle JN, Lou Z, Visscher DW, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

Breast Cancer Res. 2017 Dec 6;19(1):130. doi: 10.1186/s13058-017-0920-8.

8.

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.

Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neum├╝ller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX.

Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.

9.

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.

Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred J, Lensing JL, Chen A, Ji J, Zang Y, Erlichman C, Haluska P, Kaufmann SH.

Clin Cancer Res. 2018 Feb 15;24(4):744-752. doi: 10.1158/1078-0432.CCR-17-1590. Epub 2017 Nov 14.

PMID:
29138343
10.

The Future of Contrast-Enhanced Mammography.

Covington MF, Pizzitola VJ, Lorans R, Pockaj BA, Northfelt DW, Appleton CM, Patel BK.

AJR Am J Roentgenol. 2018 Feb;210(2):292-300. doi: 10.2214/AJR.17.18749. Epub 2017 Oct 24.

PMID:
29064748
11.

Discussion of: "The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review".

Chang JM, Kosiorek HE, Wasif N, Gray RJ, Stucky CH, Northfelt DW, Anderson KS, McCullough AE, Tolgay Ocal I, Pockaj BA.

Am J Surg. 2017 Dec;214(6):1102-1103. doi: 10.1016/j.amjsurg.2017.09.024. Epub 2017 Sep 30. No abstract available.

PMID:
29037421
12.

The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review.

Chang JM, Kosiorek HE, Wasif N, Gray RJ, Stucky CH, Northfelt DW, Anderson KS, McCullough AE, Ocal IT, Pockaj BA.

Am J Surg. 2017 Dec;214(6):1096-1101. doi: 10.1016/j.amjsurg.2017.08.024. Epub 2017 Sep 18.

PMID:
28943062
13.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

PMID:
28874413
14.

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN.

J Clin Oncol. 2017 Oct 20;35(30):3391-3400. doi: 10.1200/JCO.2017.73.3246. Epub 2017 Aug 30.

PMID:
28854070
15.

Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?

Partridge AH, Sepucha K, O'Neill A, Miller KD, Baker E, Dang CT, Northfelt DW, Sledge GW, Schneider BP.

Breast Cancer Res Treat. 2017 Oct;165(3):545-553. doi: 10.1007/s10549-017-4338-x. Epub 2017 Jun 23.

PMID:
28646344
16.

Posttransplant Lymphoproliferative Disorder: Otolaryngological Manifestations and Management.

Heyes R, Northfelt DW, Lott DG.

Otolaryngol Head Neck Surg. 2017 Nov;157(5):750-759. doi: 10.1177/0194599817707208. Epub 2017 May 23. Review.

PMID:
28535360
17.

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T.

J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2.

PMID:
28463630
18.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

19.

SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.

Dudenkov TM, Ingle JN, Buzdar AU, Robson ME, Kubo M, Ibrahim-Zada I, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Barman P, Goetz MP, Northfelt DW, Moreno-Aspita A, Williard CV, Kalari KR, Nakamura Y, Wang L, Weinshilboum RM.

Breast Cancer Res Treat. 2017 Jul;164(1):189-199. doi: 10.1007/s10549-017-4243-3. Epub 2017 Apr 20.

20.

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.

Goetz MP, Kalari KR, Suman VJ, Moyer AM, Yu J, Visscher DW, Dockter TJ, Vedell PT, Sinnwell JP, Tang X, Thompson KJ, McLaughlin SA, Moreno-Aspitia A, Copland JA, Northfelt DW, Gray RJ, Hunt K, Conners A, Sicotte H, Eckel-Passow JE, Kocher JP, Ingle JN, Ellingson MS, McDonough M, Wieben ED, Weinshilboum R, Wang L, Boughey JC.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw306.

21.

Survival benefit needed to undergo chemotherapy: Patient and physician preferences.

Vaz-Luis I, O'Neill A, Sepucha K, Miller KD, Baker E, Dang CT, Northfelt DW, Winer EP, Sledge GW, Schneider B, Partridge AH.

Cancer. 2017 Aug 1;123(15):2821-2828. doi: 10.1002/cncr.30671. Epub 2017 Mar 21.

PMID:
28323331
22.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ.

Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.

23.

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.

Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE.

Am J Hematol. 2017 May;92(5):448-453. doi: 10.1002/ajh.24671. Epub 2017 Mar 10.

24.

A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.

Ho TH, Nunez-Nateras R, Hou YX, Bryce AH, Northfelt DW, Dueck AC, Wong B, Stanton ML, Joseph RW, Castle EP.

Clin Genitourin Cancer. 2017 Apr;15(2):196-202.e1. doi: 10.1016/j.clgc.2016.08.026. Epub 2016 Sep 8.

PMID:
27771244
25.

Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge Deficit.

Padrnos L, Bennett R, Kosiorek H, Dueck AC, Northfelt D, Mikhael J, Tibes R, Khera N, Mesa RA.

J Cancer Educ. 2018 Jun;33(3):653-659. doi: 10.1007/s13187-016-1123-1.

PMID:
27730534
26.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

27.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.

28.

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.

Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA.

Cancer Res. 2016 Jul 1;76(13):3702-10. doi: 10.1158/0008-5472.CAN-15-3091. Epub 2016 Apr 20.

29.

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.

Tan WW, Allred JB, Moreno-Aspitia A, Northfelt DW, Ingle JN, Goetz MP, Perez EA.

Clin Breast Cancer. 2016 Apr;16(2):82-6. doi: 10.1016/j.clbc.2015.11.003. Epub 2015 Nov 17.

30.

Regional recurrence in the era of sentinel lymph node biopsy.

Linnaus ME, Dueck AC, Kosiorek HE, Gray RJ, Wasif N, Northfelt DW, Anderson KS, McCullough AE, Wong WW, Halyard MY, Patel SH, Pockaj BA.

Am J Surg. 2015 Dec;210(6):1155-60; discussion 1160-1. doi: 10.1016/j.amjsurg.2015.09.001. Epub 2015 Sep 28.

PMID:
26601646
31.

Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Patients.

Moustafa S, Murphy K, Nelluri BK, Northfelt D, Shah P, Lee H, Wilansky S, Naqvi TZ, Meyer S, Mookadam F.

Echocardiography. 2016 Mar;33(3):406-15. doi: 10.1111/echo.13087. Epub 2015 Oct 24.

PMID:
26498324
32.

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.

Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P.

Clin Cancer Res. 2016 Jan 15;22(2):301-9. doi: 10.1158/1078-0432.CCR-15-0588. Epub 2015 Aug 31.

33.

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.

Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA.

Oncotarget. 2015 Sep 22;6(28):26483-93. doi: 10.18632/oncotarget.4494.

34.

Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.

Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, Felten SJ, Sinnwell JP, Thompson KJ, Tang X, Vedell PT, Barman P, Sicotte H, Eckel-Passow JE, Northfelt DW, Gray RJ, McLaughlin SA, Moreno-Aspitia A, Ingle JN, Moyer AM, Visscher DW, Jones K, Conners A, McDonough M, Wieben ED, Wang L, Weinshilboum R, Boughey JC, Goetz MP.

Breast Cancer Res Treat. 2015 Sep;153(2):435-43. doi: 10.1007/s10549-015-3545-6. Epub 2015 Aug 22.

35.

Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).

Dietsch GN, Randall TD, Gottardo R, Northfelt DW, Ramanathan RK, Cohen PA, Manjarrez KL, Newkirk M, Bryan JK, Hershberg RM.

Clin Cancer Res. 2015 Dec 15;21(24):5445-52. doi: 10.1158/1078-0432.CCR-15-0578. Epub 2015 Jul 7.

36.

Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer.

Partridge AH, Sepucha K, O'Neill A, Miller KD, Motley C, Swaby RF, Schneider BP, Dang CT Jr, Northfelt DW, Sledge GW Jr.

JAMA Oncol. 2015 Jun;1(3):369-74.

37.

Factitious Disorder in Crohn's Disease: Recurrent Pancytopenia Caused by Surreptitious Ingestion of 6-Mercaptopurine.

Kahn A, Boroff ES, Martin KA, Northfelt DW, Heigh RI.

Case Rep Gastroenterol. 2015 May 7;9(2):137-41. doi: 10.1159/000382073. eCollection 2015 May-Aug.

38.

Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.

Chang JM, McCullough AE, Dueck AC, Kosiorek HE, Ocal IT, Lidner TK, Gray RJ, Wasif N, Northfelt DW, Anderson KS, Pockaj BA.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S509-15. doi: 10.1245/s10434-015-4616-y. Epub 2015 May 22.

PMID:
26001860
39.

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.

Safgren SL, Suman VJ, Kosel ML, Gilbert JA, Buhrow SA, Black JL, Northfelt DW, Modak AS, Rosen D, Ingle JN, Ames MM, Reid JM, Goetz MP.

Pharmacogenet Genomics. 2015 Apr;25(4):157-63. doi: 10.1097/FPC.0000000000000121.

40.

Quality of life and disease understanding: impact of attending a patient-centered cancer symposium.

Padrnos L, Dueck AC, Scherber R, Glassley P, Stigge R, Northfelt D, Mikhael J, Aguirre A, Bennett RM, Mesa RA.

Cancer Med. 2015 Jun;4(6):800-7. doi: 10.1002/cam4.422. Epub 2015 Jan 30.

41.

Intersection of cardiology and oncology clinical practices.

Mookadam F, Sharma A, Lee HR, Northfelt DW.

Front Oncol. 2014 Sep 24;4:259. doi: 10.3389/fonc.2014.00259. eCollection 2014. Review. No abstract available.

42.

A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.

Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD 3rd, Aubry MC, Adjei AA.

J Thorac Oncol. 2015 Jan;10(1):172-80. doi: 10.1097/JTO.0000000000000383.

43.

Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.

Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, Barman P, Dudenkov TT, Northfelt DW, Perez EA, Flockhart DA, Williard CV, Wang L, Weinshilboum RM.

Steroids. 2015 Jul;99(Pt A):32-8. doi: 10.1016/j.steroids.2014.08.007. Epub 2014 Aug 24.

44.

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.

Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW.

Br J Cancer. 2014 Sep 9;111(6):1241-8. doi: 10.1038/bjc.2014.430. Epub 2014 Aug 12.

45.

Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P.

Clin Cancer Res. 2014 Sep 15;20(18):4747-57. doi: 10.1158/1078-0432.CCR-14-0114. Epub 2014 Jul 14. Erratum in: Clin Cancer Res. 2014 Dec 1;20(23):6224. Huang, Jaiqi [corrected to Huang, Jiaqi].

46.

Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantation.

Khera N, Chang YH, Slack J, Fauble V, Leis JF, Noel P, Sproat L, Palmer J, Adams R, Fitch T, Northfelt D, Guy M, Tilburt J, Mikhael J.

Leuk Lymphoma. 2015 Apr;56(4):987-92. doi: 10.3109/10428194.2014.941834. Epub 2014 Aug 20.

PMID:
25012944
47.

A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.

Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, Manjarrez KL, Randall TD, Hershberg RM.

Clin Cancer Res. 2014 Jul 15;20(14):3683-91. doi: 10.1158/1078-0432.CCR-14-0392. Epub 2014 May 7.

48.

Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.

Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C, Alberts SR.

Invest New Drugs. 2014 Aug;32(4):710-6. doi: 10.1007/s10637-014-0096-3. Epub 2014 Apr 18.

PMID:
24740268
49.

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.

Curtis KK, Sarantopoulos J, Northfelt DW, Weiss GJ, Barnhart KM, Whisnant JK, Leuschner C, Alila H, Borad MJ, Ramanathan RK.

Cancer Chemother Pharmacol. 2014 May;73(5):931-41. doi: 10.1007/s00280-014-2424-x. Epub 2014 Mar 8.

50.

Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103.

Ruddy KJ, O'Neill A, Miller KD, Schneider BP, Baker E, Sparano JA, Dang C, Northfelt DW, Sledge GW Jr, Partridge AH.

Breast Cancer Res Treat. 2014 Apr;144(3):591-7. doi: 10.1007/s10549-014-2891-0. Epub 2014 Mar 2.

Supplemental Content

Loading ...
Support Center